Skip to main content

Table 3 Association of TACSTD2 methylation and clinicopathological parameters with recurrence free survival in bivariate survival analysis

From: DNA methylation of tumor associated calcium signal transducer 2 (TACSTD2) loci shows association with clinically aggressive renal cell cancers

  HR (95% CI) p-value
TACSTD2 methylation 2.85 (1.14–7.12) 0.025
Metastasis 4.92 (1.95–12.43) 0.001
TACSTD2 methylation 2.85 (1.14–7.16) 0.026
Tumor stage* 2.77 (1.10–6.95) 0.030
TACSTD2 methylation 3.59 (1.42–9.04) 0.007
Differentiation 11.48 (4.13–31.91) < 0.001
TACSTD2 methylation 2.37 (0.93–5.99) 0.069
State of Disease** 4.72 (1.65–13.50) 0.004
TACSTD2 methylation 3.39 (1.37–8.35) 0.008
Age 0.99 (0.95–1.03) 0.571
  1. HR hazard ratio; 95% CI 95% confidence interval
  2. *Low defined as T1 and T2; high defined as T3 and T4
  3. **Localized disease defined as pT ≤ 2, N0, M0; Advanced disease defined as pT ≥ 3 and/or N1, M1